文献速递心外重症与机械循环支持

临床试验数据在真实世界实践中的可推广性:STS Intermacs数据库分析

Generalizability of Trial Data to Real-World Practice: An Analysis of The Society of Thoracic Surgeons Intermacs Database.
PubMed 文献 · Ann Thorac Surg · 2021-10-05

本研究将MOMENTUM 3试验的入排标准应用于Intermacs数据库中4610例HeartMate 3植入患者,发现42%的患者不符合试验标准,其1年死亡率高于符合标准者(17%±1% vs 10%±1%,P<.001),且不符合标准项越多死亡率越高,但两组 outcomes 均良好,提示未来试验标准可放宽。

要点

  • 真实世界中42%的HeartMate 3患者不符合MOMENTUM 3试验标准。
  • 不符合标准者1年死亡率更高(17% vs 10%),且随不符合项数增加而升高。
  • 尽管死亡率有差异,两组患者真实世界结局均良好,支持放宽试验标准。

核心结论

  • 尽管不符合试验标准的患者死亡率更高,但符合与不符合标准的HeartMate 3接受者在真实世界实践中均获得良好结局,提示未来试验入排标准可扩展。

研究设计与样本

  • 回顾性队列分析,将MOMENTUM 3试验入排标准应用于STS Intermacs数据库中2017年8月至2020年3月接受HeartMate 3植入的4610例患者。

主要发现

  • 1941例(42%)患者不符合试验标准,其中1245例(27%)符合1项排除标准,470例(10%)符合2项,226例(5%)符合3项及以上。
  • 不符合标准者估计1年死亡率为17%±1%,高于符合标准者的10%±1%(P<.001)。
  • 与符合标准者相比,符合1项、2项、3项及以上排除标准者的1年死亡率分别为15%±1%、16%±2%、30%±3%,呈递增趋势。
  • 不符合标准患者中,血小板减少及肌酐、胆红素、INR升高与死亡率增加独立相关。

临床怎么用

  • 在真实世界实践中,即使不符合严格试验标准的患者,HeartMate 3植入后仍可获得良好结局,可考虑适当放宽选择标准。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although the current wide-scale adoption of the HeartMate 3 left ventricular assist device can be attributed to favorable clinical trial outcomes, restrictive clinical trial eligibility criteria may result in lack of generalizability to real-world populations. We assessed the generalizability of left ventricular assist device clinical trial outcomes and evaluated the prognostic value of specific inclusion and exclusion criteria. METHODS: The Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Therapy With HeartMate 3 (MOMENTUM 3) eligibility criteria were applied to patients identified in The Society of Thoracic Surgeons Interagency Registry for Mechanically Assisted Circulatory Support (Intermacs) who underwent HeartMate 3 implantation (n = 4610) between August 2017 and March 2020. Patients were categorized as trial-eligible or trial-ineligible and by number of ineligibility criteria. The effect of trial eligibility on mortality was estimated using Cox models. RESULTS: Indications for HeartMate 3 implant included destination therapy (n = 2827, 61%), bridge to candidacy (n = 969, 21%), and bridge to transplant (n = 702, 15%). A total of 1941 recipients (42%) were trial-ineligible, with 1245 (27%) meeting one ineligibility criterion, 470 (10%) meeting two, and 226 (5%) meeting three or more. Estimated 1-year mortality for trial-ineligible recipients was higher than for trial-eligible recipients (17% ± 1% vs 10% ± 1%, P < .001). Compared with trial-eligible patients, 1-year mortality was incrementally higher for patients meeting one ineligibility criterion (15% ± 1%), two criteria (16% ± 2%), and three or more criteria (30% ± 3%). Thrombocytopenia and elevated creatinine, bilirubin, and international normalized ratio in trial-ineligible patients were independently associated with increased mortality. CONCLUSIONS: Despite differences in mortality, both trial-eligible and trial-ineligible HeartMate 3 recipients had excellent outcomes in real-world practice, suggesting future trial eligibility criteria could be expanded.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Brescia AA, Watt TMF, Pagani FD, et al. Generalizability of Trial Data to Real-World Practice: An Analysis of The Society of Thoracic Surgeons Intermacs Database. Ann Thorac Surg. 2021. PMID: 34619136. doi:10.1016/j.athoracsur.2021.08.062

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。